Vial size
The mass or labeled potency in that protocol's vial. A larger vial does not automatically mean a larger research dose.
Search 141 research protocol summaries by peptide, vial size, concentration, dose range, and frequency, then open any row for the complete protocol and calculation context.
This peptide dosage chart organizes 141 research protocol entries for single peptides, premixed blends, and separate-vial stacks. Search or sort the table by peptide name, vial size, protocol concentration, dose range, and frequency. Each peptide name links to a full dosing protocol with U-100 syringe units, mL, reconstitution steps, supplies, and evidence context.
| 5-Amino-1MQ | 10 mg Vial | Single | 5 mg/mL | 2.5 mg–5 mg | Daily |
| 5-Amino-1MQ | 5 mg Vial | Single | 5 mg/mL | 2.5 mg–5 mg | Daily |
| 5-Amino-1MQ | 50 mg Vial | Single | 12.5 mg/mL | 2.5 mg–5 mg | Daily |
| Abaloparatide | 3 mg Vial | Single | 1 mg/mL | 80 mcg | Daily |
| Adamax | 10 mg Vial | Single | 3.33 mg/mL | 300 mcg–1 mg | Daily |
| Adipotide | 10 mg Vial | Single | 3.33 mg/mL | 250 mcg–1 mg | Daily |
| Adipotide | 2 mg Vial | Single | 3.33 mg/mL | 250 mcg–1 mg | Daily |
| Adipotide | 5 mg Vial | Single | 3.33 mg/mL | 250 mcg–1 mg | Daily |
| AHK-Cu | 100 mg Vial | Single | 33.33 mg/mL | 1 mg–2 mg | Daily |
| AICAR | 50 mg Vial | Single | 16.7 mg/mL | 1 mg–3 mg | Daily |
| AOD-9604 | 10 mg Vial | Single | 3.333 mg/mL | 300 mcg–500 mcg | Daily |
| AOD-9604 | 2 mg Vial | Single | 0.667 mg/mL | 300 mcg–500 mcg | Daily |
| AOD-9604 | 5 mg Vial | Single | 1.667 mg/mL | 300 mcg–500 mcg | Daily |
| AOD-9604 + CJC-1295 + Ipamorelin | 12 mg Blend | Blend | 4 mg/mL | 400 mcg–800 mcg | Daily |
| ARA-290 | 10 mg Vial | Single | 5 mg/mL | 4 mg | Daily |
| Ara-290 | 16 mg Vial | Single | 8 mg/mL | 2 mg–4 mg | Daily |
| BPC-157 | 10 mg Vial | Single | 3.33 mg/mL | 200 mcg–600 mcg | Daily |
| BPC-157 | 20 mg Vial | Single | 6.67 mg/mL | 200 mcg–600 mcg | Daily |
| BPC-157 | 40 mg Vial | Single | 13.33 mg/mL | 200 mcg–600 mcg | Daily |
| BPC-157 | 5 mg Vial | Single | 1.67 mg/mL | 200 mcg–600 mcg | Daily |
| BPC-157 + TB-500 | 10 mg Blend | Blend | 3.33 mg/mL | 500 mcg–1.5 mg | Daily |
| BPC-157 + TB-500 | 20 mg Blend | Blend | 6.67 mg/mL | 500 mcg–1.5 mg | Daily |
| Bronchogen | 20 mg Vial | Single | 6.667 mg/mL | 1 mg–2 mg | Daily |
| Cagrilintide | 10 mg Vial | Single | 3.33 mg/mL | 600 mcg–4.5 mg | Weekly |
| Cagrilintide | 5 mg Vial | Single | 5 mg/mL | 0.6 mg–4.5 mg | Weekly |
| Cagrilintide + Semaglutide | 10 mg Blend | Blend | 3.33 mg/mL | 500 mcg–4.8 mg | Weekly |
| Cardiogen | 20 mg Vial | Single | 6.667 mg/mL | 1 mg–2 mg | Daily |
| Cartalax | 20 mg Vial | Single | 6.67 mg/mL | 2 mg–5 mg | Daily |
| Cartalax | 40 mg Vial | Single | 13.33 mg/mL | 2 mg–5 mg | Daily |
| Cerebrolysin | 60 mg Vial | Single | 20 mg/mL | 20 mg–32 mg | Daily |
| Chonluten | 20 mg Vial | Single | 6.67 mg/mL | 250 mcg–4 mg | Daily |
| CJC-1295 + GHRP-2 | 10 mg Blend | Blend | 3.33 mg/mL | 150 mcg–300 mcg | Daily |
| CJC-1295 DAC | 2 mg Vial | Single | 2.0 mg/mL | 2 mg | Weekly |
| CJC-1295 DAC (2 mg) + Ipamorelin (5 mg) Stack | View protocol | Stack | 1 / 1.67 mg/mL | 1 mg–2 mg / 100 mcg–300 mcg | Weekly / Daily |
| CJC-1295 DAC | 5 mg Vial | Single | 2.5 mg/mL | 300 mcg–1 mg | Weekly |
| CJC-1295 DAC (5 mg) + Ipamorelin (5 mg) Stack | View protocol | Stack | 2.5 / 1.67 mg/mL | 1 mg–2 mg / 100 mcg–300 mcg | Weekly / Daily |
| CJC-1295 NO DAC | 5 mg Vial | Single | 1.67 mg/mL | 100 mcg–300 mcg | Daily |
| CJC-1295 NO DAC + Ipamorelin | 10 mg Blend | Blend | 3.33 mg/mL | 200 mcg–600 mcg | Daily |
| Cortagen | 20 mg Vial | Single | 6.67 mg/mL | 1 mg–2 mg | Daily |
| DSIP | 10 mg Vial | Single | 3.33 mg/mL | 100 mcg–300 mcg | Daily |
| DSIP | 5 mg Vial | Single | 1.67 mg/mL | 100 mcg–300 mcg | Daily |
| Eloralintide | 10 mg Vial | Single | 10 mg/mL | 1 mg–9 mg | Weekly |
| Epitalon (Epithalon) | 10 mg Vial | Single | 5 mg/mL | 5 mg | Daily |
| FOXO4-DRI | 10 mg Vial | Single | 3.33 mg/mL | 250 mcg–500 mcg | Daily |
| GHK-Cu | 100 mg Vial | Single | 33.33 mg/mL | 1 mg–2 mg | 3 or 5 times weekly |
| GHK-Cu | 50 mg Vial | Single | 16.67 mg/mL | 1 mg–2 mg | 5 days/week |
| GHRP-2 | 10 mg Vial | Single | 3.33 mg/mL | 100 mcg–300 mcg | Daily |
| GHRP-2 | 5 mg Vial | Single | 1.67 mg/mL | 100 mcg–200 mcg | Daily |
| GHRP-6 | 10 mg Vial | Single | 3.33 mg/mL | 100 mcg–300 mcg | Daily |
| GHRP-6 | 2 mg Vial | Single | 0.67 mg/mL | 100 mcg–300 mcg | Daily |
| GHRP-6 | 5 mg Vial | Single | 1.67 mg/mL | 100 mcg–300 mcg | Daily |
| GLOW | 70 mg Blend | Blend | 23.3 mg/mL | 2,330 mcg | Daily |
| Glutathione | 600 mg Vial | Single | 300 mg/mL | 100 mg–200 mg | Daily |
| Gonadorelin | 2 mg Vial | Single | 1 mg/mL | 50 mcg–150 mcg | Weekly |
| HCG | 10000 IU Vial | Single | 5,000 IU/mL | 500 IU–2,000 IU | 3 times weekly |
| HCG | 2000 IU Vial | Single | Unverified | 500 IU–2,000 IU | 3 times weekly |
| HCG | 4000 IU Vial | Single | 2,000 IU/mL | 500 IU–2,000 IU | 3 times weekly |
| HCG | 5000 IU Vial | Single | 2,500 IU/mL | 500 IU–2,000 IU | 3 times weekly |
| HGH 191AA | 10IU Vial | Single | 1.11 mg/mL | 200 mcg–900 mcg | Daily |
| HMG | 0.15 mg / 75 IU Vial | Single | 75 IU/mL | 75 IU | 3 times weekly |
| Humanin | 10 mg Vial | Single | 3.333 mg/mL | 1 mg–3 mg | Twice weekly |
| IGF-1 LR3 | 1 mg Vial | Single | 0.333 mg/mL | 20 mcg–50 mcg | Daily |
| Ipamorelin | 10 mg Vial | Single | 3.33 mg/mL | 100 mcg–250 mcg | Daily |
| Ipamorelin | 5 mg Vial | Single | 1.67 mg/mL | 100 mcg–250 mcg | Daily |
| Kisspeptin | 10 mg Vial | Single | 3.33 mg/mL | 100 mcg–200 mcg | Daily |
| KLOW | 80 mg Blend | Blend | 26.7 mg/mL | 2 mg–6 mg | Daily |
| KPV | 10 mg Vial | Single | 3.33 mg/mL | 200 mcg–500 mcg | Daily |
| L-Carnitine | 200 mg Vial | Single | 100 mg/mL | 50 mg–100 mg | Daily |
| Livagen | 20 mg Vial | Single | 6.67 mg/mL | 500 mcg–2 mg | Daily |
| LL-37 | 5 mg Vial | Single | 1.67 mg/mL | 50 mcg–400 mcg | Daily / 5 days weekly |
| Mazdutide | 10 mg Vial | Single | 3.33 mg/mL | 2.5 mg–5 mg | Weekly |
| Mazdutide | 5 mg Vial | Single | 1.67 mg/mL | 2.5 mg–5 mg | Weekly |
| Melanotan I | 10 mg Vial | Single | 10 mg/mL | 5.6 mg | 5 days/week |
| Melanotan II | 10 mg Vial | Single | 3.33 mg/mL | 250 mcg–1 mg | Daily |
| MGF | 5 mg Vial | Single | 1.67 mg/mL | 100 mcg–300 mcg | Daily |
| MOTS-C | 10 mg Vial | Single | 3.33 mg/mL | 200 mcg–1 mg | Daily |
| MOTS-C | 20 mg Vial | Single | 6.67 mg/mL | 200 mcg–1 mg | Daily |
| MOTS-C | 40 mg Vial | Single | 13.33 mg/mL | 200 mcg–1 mg | Daily |
| MOTS-C | 5 mg Vial | Single | 1.67 mg/mL | 500 mcg–2 mg | Daily |
| NAD+ | 1000 mg Vial | Single | 333.33 mg/mL | 50 mg–100 mg | Daily |
| NAD+ | 500 mg Vial | Single | 166.67 mg/mL | 50 mg–100 mg | Daily |
| Neuroxelin | 48 mg Vial | Blend | 16 mg/mL | 500 mcg–750 mcg | Daily |
| Ovagen | 20 mg Vial | Single | 10 mg/mL | 10 mcg–150 mcg | Daily |
| Oxytocin | 10 mg Vial | Single | 3.33 mg/mL | 100 mcg–500 mcg | Daily |
| Oxytocin | 5 mg Vial | Single | 1.67 mg/mL | 100 mcg–500 mcg | Daily |
| PE-22-28 | 10 mg Vial | Single | 3.33 mg/mL | 50 mcg–200 mcg | Daily |
| PEG MGF | 2 mg Vial | Single | 0.667 mg/mL | 200 mcg–500 mcg | Daily |
| Pinealon | 20 mg Vial | Single | 6.67 mg/mL | 1 mg–2 mg | Daily |
| PNC-27 | 30 mg Vial | Single | 10 mg/mL | 100 mcg–500 mcg | Daily |
| Prostamax | 20 mg Vial | Single | 10 mg/mL | 500 mcg–1 mg | Daily |
| PT-141 | 10 mg Vial | Single | 3.33 mg/mL | 500 mcg–1.5 mg | Daily |
| PT-141 (10 mg) + Melanotan II (10 mg) Stack | View protocol | Stack | 3.33 mg/mL each | 500 mcg–1,750 mcg / 250 mcg–1,000 mcg | On demand / Daily, then 2–3 times weekly |
| Retatrutide Dosage Protocol | 10 mg Vial | Single | 10.0 mg/mL | 2 mg–8 mg | Weekly |
| Retatrutide Dosage Protocol | 20 mg Vial | Single | 10.0 mg/mL | 2 mg–8 mg | Weekly |
| Retatrutide Dosage Protocol | 30 mg Vial | Single | 10.0 mg/mL | 2 mg–8 mg | Weekly |
| Retatrutide Dosage Protocol | 40 mg Vial | Single | 20 mg/mL | 2 mg–12 mg | Weekly |
| Retatrutide Dosage Protocol | 5 mg Vial | Single | 5.0 mg/mL | 2 mg–8 mg | Weekly |
| Retatrutide Dosage Protocol | 50 mg Vial | Single | 20 mg/mL | 2 mg–12 mg | Weekly |
| Retatrutide Dosage Protocol | 60 mg Vial | Single | 20 mg/mL | 2 mg–12 mg | Weekly |
| Selank 5 mg Dosage Chart and Protocol | View protocol | Single | 0.5 / 1 / 1.5 mg/mL | 300 mcg | 3 times daily |
| Selank Dosage (10 mg Vial) Protocol | View protocol | Single | 1 / 1.5 / 2 mg/mL | 300 mcg | 3 times daily |
| Semaglutide | 10 mg Vial | Single | 3.33 mg/mL | 250 mcg–2.4 mg | Weekly |
| Semaglutide | 15 mg Vial | Single | 5 mg/mL | 250 mcg–2.4 mg | Weekly |
| Semaglutide | 20 mg Vial | Single | 6.67 mg/mL | 250 mcg–2.4 mg | Weekly |
| Semaglutide | 30 mg Vial | Single | 10 mg/mL | 250 mcg–2.4 mg | Weekly |
| Semaglutide | 5 mg Vial | Single | 2.5 mg/mL | 250 mcg–2.4 mg | Weekly |
| Semax Dosage (10 mg Vial) Protocol | View protocol | Single | 1 or 2 mg/mL | 200 mcg–300 mcg | 2–3 times daily |
| Semax Dosage (5 mg Vial) Protocol | View protocol | Single | 0.5 or 1 mg/mL | 200 mcg–300 mcg | 2–3 times daily |
| Sermorelin | 10 mg Vial | Single | 3.33 mg/mL | 200 mcg–500 mcg | Daily |
| Sermorelin 5 mg Dosage Chart and Protocol | View protocol | Single | 1.67 mg/mL | 200 mcg–500 mcg | Once daily at bedtime |
| SLU-PP-332 | 5 mg Vial | Single | 1.67 mg/mL | 625 mcg–1,250 mcg | Twice daily (mouse) |
| SNAP-8 Dosage: 10 mg Topical Research Guide | View protocol | Single | 0.0015–0.005% active w/w | Not specified | Not specified |
| SS-31 | 10 mg Vial | Single | 10 mg/mL | 5 mg–20 mg | Daily |
| SS-31 | 30 mg Vial | Single | 10 mg/mL | 5 mg–10 mg | Daily |
| SS-31 | 50 mg Vial | Single | 16.67 mg/mL | 5 mg–10 mg | Daily |
| Survodutide | 10 mg Vial | Single | 5 mg/mL | 0.6 mg–6 mg | Weekly |
| TB-500 | 10 mg Vial | Single | 3.33 mg/mL | 500 mcg–1 mg | Daily |
| TB-500 | 5 mg Vial | Single | 1.67 mg/mL | 500 mcg–1 mg | Daily |
| TB-500 (5 mg) + BPC-157 (5 mg) Stack | View protocol | Stack | 2.5 mg/mL each | 1.25 mg / 250 mcg–500 mcg | Twice weekly, then weekly / Daily |
| Teriparatide | 750 mcg Vial | Single | 250 mcg/mL | 20 mcg | Daily |
| Tesamorelin | 10 mg Vial | Single | 3.33 mg/mL | 2 mg | Daily |
| Tesamorelin | 20 mg Vial | Single | 6.67 mg/mL | 2 mg | Daily |
| Tesamorelin | 5 mg Vial | Single | 2 mg/mL | 2 mg | Daily |
| Tesamorelin 5mg + Ipamorelin 5mg | 10mg Blend | Blend | 3.33 mg/mL | Unverified | Daily |
| Testagen | 20 mg Vial | Single | 6.67 mg/mL | 100 mcg–300 mcg | Daily |
| Thymosin Alpha-1 | 10 mg Vial | Single | 3.33 mg/mL | 300 mcg–500 mcg | Daily |
| Thymosin Alpha-1 | 5 mg Vial | Single | 1.67 mg/mL | 300 mcg–500 mcg | Daily |
| Tirzepatide | 10 mg Vial | Single | 5.0 mg/mL | 2.5 mg–10 mg | Weekly |
| Tirzepatide | 100 mg Vial | Single | 40 mg/mL | 2.5 mg–15 mg | Weekly |
| Tirzepatide | 15 mg Vial | Single | 7.5 mg/mL | 2.5 mg–10 mg | Weekly |
| Tirzepatide | 20 mg Vial | Single | 10 mg/mL | 2.5 mg–15 mg | Weekly |
| Tirzepatide | 30 mg Vial | Single | 10.0 mg/mL | 2.5 mg–10 mg | Weekly |
| Tirzepatide | 40 mg Vial | Single | 20 mg/mL | 2.5 mg–15 mg | Weekly |
| Tirzepatide | 5 mg Vial | Single | 2.5 mg/mL | 2.5 mg–10 mg | Weekly |
| Tirzepatide | 50 mg Vial | Single | 20 mg/mL | 2.5 mg–15 mg | Weekly |
| Tirzepatide | 60 mg Vial | Single | 20 mg/mL | 2.5 mg–15 mg | Weekly |
| Tirzepatide | 80 mg Vial | Single | 40 mg/mL | 2.5 mg–15 mg | Weekly |
| Tirzepatide | 90 mg Vial | Single | 40 mg/mL | 2.5 mg–15 mg | Weekly |
| Tri-Heal | 45 mg Blend | Blend | 15 mg/mL | 500 mcg–2 mg | Daily |
| Vesugen (Lys-Glu-Asp) | 20 mg Vial | Single | 6.67 mg/mL | 500 mcg–2 mg | Daily |
| Vilon | 20 mg Vial | Single | 6.67 mg/mL | 67 mcg–667 mcg | Daily |
Quick reference
Each row is a compact index of one published protocol page. It is not a stand-alone recommendation. Click the peptide name before interpreting a dose range because the linked page identifies the schedule, route, formulation, calculation basis, and evidence limits.
The mass or labeled potency in that protocol's vial. A larger vial does not automatically mean a larger research dose.
The mass per mL produced by the final volume documented on the linked protocol page. The required diluent is product-specific.
The amount range summarized from the linked research protocol. Choose View chart for its complete phases, options, and context. It is not a universal range for every formulation, route, or research setting.
The schedule category shown by that protocol. Open the page for the exact period, timing, phases, and units per administration.
Calculation guide
The chart separates peptide mass from liquid volume. Milligrams and micrograms describe mass; milliliters describe the volume drawn. The final concentration connects the two.
Worked calculation: a 10 mg vial prepared to 2 mL has a concentration of 5 mg/mL. A 500 mcg calculation equals 0.5 mg, which is 0.10 mL or 10 markings on a U-100 syringe. U-100 means 100 units per mL; these are volume markings, not peptide International Units (IU).[1]
Use the peptide dosage calculator for the arithmetic, the peptide reconstitution guide for the preparation workflow, and the syringe measurement guide for U-100 markings and measurement limits.
Chart categories
One named compound and its vial-specific calculation. Compare strengths within the same family without assuming that vial mass changes the protocol amount range.
Browse single peptidesTwo or more compounds supplied in one vial. The full protocol keeps the total blend amount and each component explicit.
Browse peptide blendsTwo or more products used in one research schedule while retaining independent vial identity, concentration, and preparation instructions.
Browse peptide stacksEvidence context
A peptide dosing protocol can summarize different levels of evidence. Some pages translate amounts and schedules reported in human clinical trial data. Others identify community-reported use when no validated human regimen exists, or provide calculation-only examples when evidence is insufficient for a protocol claim. The linked page states which basis applies.
Use the master chart to find a compound and strength, then use the complete peptide dosing guide for its week or phase, amount per administration, frequency, U-100 units, mL, reconstitution steps, storage notes, and published research context.
Peptide dosage FAQ
Divide vial mass by final liquid volume to find concentration. Convert the selected mass into the same unit, divide it by concentration to find mL, then multiply mL by 100 for U-100 syringe markings. Use the linked protocol's verified final volume and diluent rather than assuming one universal mixture.
First calculate the volume in mL from the peptide mass and concentration. On a U-100 syringe, 1 mL equals 100 units, so 0.10 mL equals 10 syringe units. These markings describe liquid volume and must not be confused with peptide IU.
Not by itself. Vial size changes how much material is available and can change concentration, draw volume, vial duration, and supply counts. The evidence and protocol determine the amount and frequency, not the vial label alone.
Each linked protocol explains its basis. Pages distinguish published human research from community-reported use and calculation-only examples, and they identify important formulation, route, and evidence limitations beside the relevant chart.
No. The master chart is a quick reference and directory. Open the linked protocol before using any row because the complete page supplies the schedule, U-100 units, mL, reconstitution, storage, supplies, citations, and limitations needed to interpret it.
No. It is an educational research reference and does not establish a safe, effective, or approved regimen for any person. Peptides on this site are discussed for laboratory and research purposes only.